152 related articles for article (PubMed ID: 36447064)
21. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
[TBL] [Abstract][Full Text] [Related]
22. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
23. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
[TBL] [Abstract][Full Text] [Related]
24. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Lee EK; Fader AN; Santin AD; Liu JF
Gynecol Oncol; 2021 Jan; 160(1):322-332. PubMed ID: 33160694
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
27. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers S; Secord AA; Havrilesky L; O'Malley DM; Backes FJ; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi K; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
Clin Cancer Res; 2020 Aug; 26(15):3928-3935. PubMed ID: 32601075
[TBL] [Abstract][Full Text] [Related]
28. New Treatments for Recurrent Uterine Cancer.
Toboni MD; Powell MA
Curr Oncol Rep; 2021 Nov; 23(12):139. PubMed ID: 34735648
[TBL] [Abstract][Full Text] [Related]
29. A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer.
Sun B; Zhao N; Cheng Y; Wang J
Mol Biol Rep; 2023 Aug; 50(8):6901-6912. PubMed ID: 37326746
[TBL] [Abstract][Full Text] [Related]
30. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy in the treatment of uterine serous carcinoma.
Schwab CL; Santin AD
Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
[No Abstract] [Full Text] [Related]
32. Ryanodine receptor 1-mediated Ca
Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
[TBL] [Abstract][Full Text] [Related]
33. Uterine serous carcinoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Nout RA; Lorusso D; Vaughan MM; Bini M; Takano M; Provencher D; Indini A; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Candido Dos Reis FJ; Lopez S; Mariani A; Leitao MM; Raspagliesi F; Panici PB; Di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2021 Jul; 162(1):226-234. PubMed ID: 33934848
[TBL] [Abstract][Full Text] [Related]
34. Early stage uterine serous carcinoma: management updates and genomic advances.
Fader AN; Santin AD; Gehrig PA
Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
[TBL] [Abstract][Full Text] [Related]
35. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
[TBL] [Abstract][Full Text] [Related]
37. Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report.
Mao S; Desravines N; Zarei S; Viswanathan AN; Fader AN
Gynecol Oncol Rep; 2023 Oct; 49():101250. PubMed ID: 37575611
[TBL] [Abstract][Full Text] [Related]
38. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.
Frimer M; Miller EM; Shankar V; Girda E; Mehta K; Smith HO; Kuo DYS; Goldberg GL; Einstein MH
Int J Gynecol Cancer; 2018 Nov; 28(9):1781-1788. PubMed ID: 30371562
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]